MA20150026A1 - Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés - Google Patents

Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés

Info

Publication number
MA20150026A1
MA20150026A1 MA37387A MA37387A MA20150026A1 MA 20150026 A1 MA20150026 A1 MA 20150026A1 MA 37387 A MA37387 A MA 37387A MA 37387 A MA37387 A MA 37387A MA 20150026 A1 MA20150026 A1 MA 20150026A1
Authority
MA
Morocco
Prior art keywords
cells
methods
pluripotent stem
isolating
human
Prior art date
Application number
MA37387A
Other languages
English (en)
Inventor
Aziz Aris
Original Assignee
Sct & B Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sct & B Inc filed Critical Sct & B Inc
Publication of MA20150026A1 publication Critical patent/MA20150026A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention concerne une population isolée de cellules souches pluripotentes placentaire humain ou une cellule souche pluripotente placentaire humaine isolée positive à l'antigène leucocytaire humain g (hla-g), un marqueur de migration et au moins un marqueur de cellules souches pluripotentes. La présente description concerne en outre un procédé pour isoler des cellules souches pluripotentes placentaires humaines. Le procédé comprend les étapes suivantes : extraction de cellules à partir d'un placenta humain; et isolation des cellules positives à l'antigène leucocytaire humain g (hla-g), un marqueur de migration et au moins un marqueur de cellules souches pluripotentes et utilisation de ceux-ci. D'autre part, il est probable que la présente description soit applicable à des primates et à d'autres animaux.
MA37387A 2012-03-06 2013-03-06 Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés MA20150026A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607150P 2012-03-06 2012-03-06
PCT/CA2013/050167 WO2013131192A1 (fr) 2012-03-06 2013-03-06 Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés

Publications (1)

Publication Number Publication Date
MA20150026A1 true MA20150026A1 (fr) 2015-01-30

Family

ID=49115831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37387A MA20150026A1 (fr) 2012-03-06 2013-03-06 Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés

Country Status (9)

Country Link
US (1) US20150056170A1 (fr)
EP (1) EP2823038A4 (fr)
JP (1) JP2015509508A (fr)
CN (1) CN104284976A (fr)
AU (1) AU2013230653A1 (fr)
CA (1) CA2865934A1 (fr)
IN (1) IN2014DN08217A (fr)
MA (1) MA20150026A1 (fr)
WO (1) WO2013131192A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014348600A1 (en) * 2013-11-14 2016-06-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Veterans Affairs Non-expanded post-natal multilineage-inducible cells
JP2017500316A (ja) * 2013-12-13 2017-01-05 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復する方法
CN103756967B (zh) * 2013-12-31 2018-09-21 卢英 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235563A1 (en) * 2002-04-19 2003-12-25 Strom Stephen C. Placental derived stem cells and uses thereof
ZA200803930B (en) * 2005-10-13 2010-03-31 Anthrogenesis Corp Immunomodulation using placental stem cells
WO2007079183A2 (fr) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Populations de cellules souches placentaires
EP2137297A4 (fr) * 2007-04-11 2010-04-14 Roger Deutsch Procédés de diagnostic d'échantillons biologiques contenant des cellules souches
KR20200143506A (ko) * 2008-08-20 2020-12-23 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
CN101748099A (zh) * 2008-12-09 2010-06-23 赵宏喜 稳定表达hla-g分子的人胚胎干细胞分化细胞
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
FR2967579B1 (fr) * 2010-11-23 2013-11-22 Ets Francais Du Sang Utilisation d'une isoforme d'hla-g comme agent anti-resorption osseuse

Also Published As

Publication number Publication date
US20150056170A1 (en) 2015-02-26
CA2865934A1 (fr) 2013-09-12
IN2014DN08217A (fr) 2015-05-15
WO2013131192A1 (fr) 2013-09-12
JP2015509508A (ja) 2015-03-30
AU2013230653A1 (en) 2014-10-23
EP2823038A1 (fr) 2015-01-14
CN104284976A (zh) 2015-01-14
EP2823038A4 (fr) 2015-08-19

Similar Documents

Publication Publication Date Title
MA20150026A1 (fr) Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés
MY173793A (en) New pcr sequencing method and use thereof in hla genotyping
WO2011087760A3 (fr) Procédés et kits pour identifier une aneuploïdie
BR112017003620A2 (pt) métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
AU2017246480A8 (en) Isolation and analysis of fetal DNA from extravillous trophoblast cells retrieved from the endocervical canal
CL2011002558A1 (es) Metodo y dispositivo para la preparacion de al menos un compuesto a partir de sangre, el cual comprende los pasos de a) disponer de sangre en un contenedor cerrado a baja presion, b) separar la sangre en fracciones (por centrifugacion o sedimentacion), c) introducir un dispositivo de extraccion hasta la fraccion superior de la sangre fraccionada, d) conectar el dispositivo de extraccion con menor presion que el contenedor y transferir la fraccion deseada.
EA202193200A1 (ru) Выделение фетальных клеток с помощью facs
BR112015009042A8 (pt) Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
MY197112A (en) Method for agglutinating erythrocytes, method for separating erythrocytes, and hemagglutination reagent
MX2016006551A (es) Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.
TN2015000231A1 (fr) Marqueurs moléculaires et méthodes pour l'identification des génotypes de palmier dattier
Schneppenheim et al. Signal-peptide-peptidase-like 2a is required for CD74 intramembrane proteolysis in human B cells
EP2117592A4 (fr) Procedes et compositions destines a reduire des populations cellulaires specifiques dans du sang et/ou des tissus
GB201021499D0 (en) Detection of quantative genetic differnces
WO2012061291A3 (fr) Procédés et compositions pour la séparation cellulaire de tissus sanguins
PL403996A1 (pl) Sposób jednoczesnej detekcji bakterii i grzybów w preparacie biologicznym metodą PCR, startery oraz zestaw do detekcji bakterii i grzybów
FR2986071A1 (fr) Procede pour pronostiquer,in vitro, dans un echantillon sanguin, la probabilite pour un patient d'evoluer vers une dengue severe
JP5888852B2 (ja) 免疫不全動物を用いた細胞の製法
WO2012018927A3 (fr) Génotypage hautement multiplexe utilisant des échantillons de sang réduit en leucocytes
WO2012076741A8 (fr) Cellules mères mésenchymateuses isolées à partir de sang périphérique
WO2011025544A3 (fr) Essais prédictifs pour l'efficacité de transplantation de cellules et procédés d'utilisation de cellules neuropotentiatrices humaines
Ibrahim et al. Evolutionary conservation of RNA editing in the genus Leishmania
MD434Z (en) Method of predicting the course of endogenous uveitis
Pennarossa et al. Expression and localization of the chaperone protein MRJ in pig gametes and gonads
WO2012112865A3 (fr) Compositions et procédés destinés à prévenir la transformation cellulaire et la métastase cancéreuse